Shares in MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) rocketed 28% after the group said its clinically-tested food supplement was able to reduce severe symptoms of long Covid.
Managing director Roby Zomer hailed the results of the study as a "real breakthrough".
The data read-out showed ArtemiC Support had a statistically significant impact on shortness of breath, cough, lack of energy, headache and mental confusion.
Zomer told investors: “The results of this trial represent a real breakthrough for the company, and are another step forward in demonstrating the ArtemiC range of product's efficacy in treating patients suffering from both Covid and long Covid.
"Given previous trials, we were optimistic that ArtemiC would prove effective in the current trials.
“However, it is this extremely gratifying to see this born out in a clinical trial undertaken by a third party, and we are all very excited about the results and what this means for making our products available to patients who have been suffering from COVID-19 and related diseases for far too long.”
The evaluation of 150 people with long Covid was an open-label study designed to assess both the safety and efficacy of the oral spray.
It is the second product from the range to show efficacy in Covid. It scored a phase II trial success in 2020 in patients with moderate symptoms of the virus.
ArtemiC Support contains natural ingredients such as Boswellia Serrata, Curcuma Longa and vitamin c.
The shares advanced 0.27p to 1.25p.